Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach

Bibliography

• International Agency for Research on Cancer. World Cancer Report 2014. Lyon; France: 2014
   Google Scholar
• Cancer treatment types. 2014. Available from: http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/index [Last accessed 19 August 2014]
   Google Scholar
• Iyer AK, Singh A, Ganta S, Amiji MM. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev 2013;65:1784-802
   PubMed Web of Science ®Google Scholar
• Hermann PC, Bhaskar S, Cioffi M, Heeschen C. Cancer stem cells in solid tumors. Semin Cancer Biol 2010;20:77-84
   PubMed Web of Science ®Google Scholar
• Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989;8:98-101
   PubMed Web of Science ®Google Scholar
• Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs 2009;1:12-25
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8
   PubMed Web of Science ®Google Scholar
• Greve B, Kelsch R, Spaniol K, et al. Flow cytometry in cancer stem cell analysis and separation. Cytometry A 2012;81:284-93
   PubMedGoogle Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68
   PubMed Web of Science ®Google Scholar
• Sell S. On the stem cell origin of cancer. Am J Pathol 2010;176:2584-494
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15
   PubMed Web of Science ®Google Scholar
• Liu S, Cong Y, Wang D, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep 2013;2:78-91
   PubMed Web of Science ®Google Scholar
• Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012;22:457-72
   PubMed Web of Science ®Google Scholar
• Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) 2012;7:597-615
   PubMed Web of Science ®Google Scholar
• Dirks PB. Brain tumor stem cells: bringing order to the chaos of brain cancer. J Clin Oncol 2008;26:2916-24
   PubMed Web of Science ®Google Scholar
• Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-85
   PubMed Web of Science ®Google Scholar
• Study indicates some anti-cancer drugs induce stem cell tumors. Available from: http://www.stemcellsportal.com/content/study-indicates-some-anti-cancer-drugs-induce-stem-cell-tumors [Last accessed 28 July 2014]
   Google Scholar
• Stewart DJ, Chiritescu G, Dahrouge S, et al. Chemotherapy dose – response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev 2007;33:101-37
   PubMed Web of Science ®Google Scholar
• Borst P. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol 2012;2:120066
   PubMedGoogle Scholar
• Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010;140:62-73
   PubMed Web of Science ®Google Scholar
• Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006;12:5615-21
   PubMed Web of Science ®Google Scholar
• Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-7
   PubMed Web of Science ®Google Scholar
• Li L, Bhatia R. Stem cell quiescence. Clin Cancer Res 2011;17:4936-41
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Haenisch S. Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol Biol 2010;596:95-121
   PubMedGoogle Scholar
• Hyde SC, Emsley P, Hartshorn MJ, et al. Structural model of ATP-binding proteing associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990;346:362-5
   PubMed Web of Science ®Google Scholar
• Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001;42:1007-17
   PubMed Web of Science ®Google Scholar
• Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006;7:861-79
   PubMed Web of Science ®Google Scholar
• Angelastro JM, Lame MW. Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol Cancer Res 2010;8:1105-15
   PubMed Web of Science ®Google Scholar
• Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature 2008;451:345-9
   PubMed Web of Science ®Google Scholar
• Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65:4320-33
   PubMed Web of Science ®Google Scholar
• Zhao Y, Alakhova DY, Kabanov AV. Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev 2013;65:1763-83
   PubMed Web of Science ®Google Scholar
• Shigeta J, Katayama K, Mitsuhashi J, et al. BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization. Cancer Sci 2010;101:1813-21
   PubMed Web of Science ®Google Scholar
• Hu C, Li H, Li J, et al. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 2008;29:2289-97
   PubMed Web of Science ®Google Scholar
• Blanpain C, Mohrin M, Sotiropoulou PA, et al.A-damage response in tissue-specific and cancer stem cells. Cell Stem Cell 2011;8:16-29
   PubMed Web of Science ®Google Scholar
• Rossi DJ, Jamieson CH, Weissman IL. Stems cells and the pathways to aging and cancer. Cell 2008;132:681-96
   PubMed Web of Science ®Google Scholar
• Bolton-Gillespie E, Schemionek M, Klein HU, et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 2013;121:4175-83
   PubMed Web of Science ®Google Scholar
• Viale A, De Franco F, Orleth A, et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009;457:51-6
   PubMed Web of Science ®Google Scholar
• Zhang M, Behbod F, Atkinson RL, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008;68:4674-82
   PubMed Web of Science ®Google Scholar
• Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-3
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444(7120):756-60
   PubMed Web of Science ®Google Scholar
• Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714-26
   PubMed Web of Science ®Google Scholar
• Domen J, Gandy KL, Weissman IL. Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. Blood 1998;91:2272-82
   PubMed Web of Science ®Google Scholar
• Tagscherer KE, Fassl A, Campos B, et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008;27:6646-56
   PubMed Web of Science ®Google Scholar
• Loebinger MR, Sage EK, Davies D, Janes SM. TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population. Br J Cancer 2010;103:1692-7
   PubMedGoogle Scholar
• Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007;1:389-402
   PubMed Web of Science ®Google Scholar
• Borovski T, De Sousa EMF, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res 2011;71:634-9
   PubMed Web of Science ®Google Scholar
• Li L, Cole J, Margolin DA. Cancer stem cell and stromal microenvironment. Ochsner J 2013;13:109-18
   PubMedGoogle Scholar
• Iwasaki H, Suda T. Cancer stem cells and their niche. Cancer Sci 2009;100:1166-72
   PubMed Web of Science ®Google Scholar
• Smith BH, Gazda LS, Conn BL, et al. Three-dimensional culture of mouse renal carcinoma cells in agarose macrobeads selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties. Cancer Res 2011;71:716-24
   PubMed Web of Science ®Google Scholar
• Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 2011;121:3804-9
   PubMed Web of Science ®Google Scholar
• Ginestier C, Liu S, Diebel ME, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010;120:485-97
   PubMed Web of Science ®Google Scholar
• Seidel S, Garvalov BK, Wirta V, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010;133:983-95
   PubMed Web of Science ®Google Scholar
• Chaturvedi P, Gilkes DM, Takano N, Semenza GL. Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc Natl Acad Sci USA 2014;111:E2120-9
   PubMedGoogle Scholar
• Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009;15:501-13
   PubMed Web of Science ®Google Scholar
• Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 2013;34:732-40
   PubMed Web of Science ®Google Scholar
• Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011;8:97-106
   PubMed Web of Science ®Google Scholar
• Holland JD, Klaus A, Garratt AN, Birchmeier W. Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol 2013;25:254-64
   PubMed Web of Science ®Google Scholar
• Krausova M, Korinek V. Wnt signaling in adult intestinal stem cells and cancer. Cell Signal 2014;26:570-9
   PubMed Web of Science ®Google Scholar
• Cui J, Jiang W, Wang S, et al. Role of Wnt/beta-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des 2012;18:2464-71
   PubMed Web of Science ®Google Scholar
• Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010;16:3153-62
   PubMed Web of Science ®Google Scholar
• Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 2013;19:1410-22
   PubMed Web of Science ®Google Scholar
• Ramaswamy B, Lu Y, Teng KY, et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res 2012;72:5048-59
   PubMed Web of Science ®Google Scholar
• Merchant AA, Matsui W. Targeting Hedgehog – a cancer stem cell pathway. Clin Cancer Res 2010;16:3130-40
   PubMed Web of Science ®Google Scholar
• Patrawala L, Calhoun T, Schneider-Broussard R, et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005;65:6207-19
   PubMed Web of Science ®Google Scholar
• David CS, Lee SR, Rashmi C, et al. First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors. J Clin Oncol 2013(Suppl):abstract 2540
   Google Scholar
• Development status of OncoMed’s anti-CSC programs. 2014. Available from: http://www.oncomed.com/Pipeline.html [Last Accessed 19 August 2014]
   Google Scholar
• Oskarsson T, Batlle E, Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 2014;14:306-21
   PubMed Web of Science ®Google Scholar
• Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013;31:539-44
   PubMed Web of Science ®Google Scholar
• Gupta PB, Fillmore CM, Jiang G, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011;146:633-44
   PubMed Web of Science ®Google Scholar
• Watabe T, Miyazono K. Roles of TGF-[beta] family signaling in stem cell renewal and differentiation. Cell Res 2009;19:103-15
   PubMed Web of Science ®Google Scholar
• Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012;22:396-403
   PubMed Web of Science ®Google Scholar
• Grange C, Tapparo M, Collino F, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res 2011;71:5346-56
   PubMed Web of Science ®Google Scholar
• Stankic M, Pavlovic S, Chin Y, et al. TGF-beta-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep 2013;5:1228-42
   PubMed Web of Science ®Google Scholar
• Ocana OH, Corcoles R, Fabra A, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012;22:709-24
   PubMed Web of Science ®Google Scholar
• Lang JY, Hsu JL, Meric-Bernstam F, et al. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 2011;20:341-56
   PubMed Web of Science ®Google Scholar
• Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-59
   PubMed Web of Science ®Google Scholar
• Yu F, Yao H, Zhu P, et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-23
   PubMed Web of Science ®Google Scholar
• Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488:522-6
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84
   PubMed Web of Science ®Google Scholar
• Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 2008;1:93-105
   PubMedGoogle Scholar
• Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010;10:147-56
   PubMed Web of Science ®Google Scholar
• Corso S, Giordano S. Targeted therapies in cancer and mechanisms of resistance. J Mol Med (Berl) 2014;92:677-9
   PubMed Web of Science ®Google Scholar
• Lackner MR, Wilson TR, Settleman J. Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol 2012;8:999-1014
   PubMed Web of Science ®Google Scholar
• Wang K, Wu X, Wang J, Huang J. Cancer stem cell theory: therapeutic implications for nanomedicine. Int J Nanomedicine 2013;8:899-908
   PubMed Web of Science ®Google Scholar
• Naor D, Nedvetzki S, Golan I, et al. CD44 in cancer. Crit Rev Clin Lab Sci 2002;39:527-79
   PubMed Web of Science ®Google Scholar
• Platt VM, Szoka FCJr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 2008;5:474-86
   PubMed Web of Science ®Google Scholar
• Goodarzi N, Ghahremani MH, Amini M, et al. CD44-targeted docetaxel conjugate for cancer cells and cancer stem-like cells: a novel hyaluronic acid-based drug delivery system. Chem Biol Drug Des 2014;83:741-52
   PubMed Web of Science ®Google Scholar
• Yoon HY, Kim HR, Saravanakumar G, et al. Bioreducible hyaluronic acid conjugates as siRNA carrier for tumor targeting. J Control Release 2013;172:653-61
   PubMed Web of Science ®Google Scholar
• Ogawa K, Yoshioka Y, Isohashi F, et al. Radiotherapy targeting cancer stem cells: current views and future perspectives. Anticancer Res 2013;33:747-54
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang J, Rhim JS, Kopeček J. HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects. J Control Release 2013;172:946-53
   PubMed Web of Science ®Google Scholar
• Sun T-M, Wang Y-C, Wang F, et al. Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. Biomaterials 2014;35:836-45
   PubMed Web of Science ®Google Scholar
• Wei X, Senanayake TH, Warren G, Vinogradov SV. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjug Chem 2013;24:658-68
   PubMed Web of Science ®Google Scholar
• Fong D, Yeh A, Naftalovich R, et al. Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett 2010;293:65-72
   PubMed Web of Science ®Google Scholar
• Lim KJ, Bisht S, Bar EE, et al. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther 2011;11:464-73
   PubMed Web of Science ®Google Scholar
• Chenna V, Hu C, Pramanik D, et al. A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Mol Cancer Ther 2012;11:165-73
   PubMed Web of Science ®Google Scholar
• Li R-J, Ying X, Zhang Y, et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J Control Release 2011;149:281-91
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu W-L, Guo J, et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Control Release 2008;129:18-25
   PubMed Web of Science ®Google Scholar
• Ma X, Zhou J, Zhang C-X, et al. Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. Biomaterials 2013;34:4452-65
   PubMed Web of Science ®Google Scholar
• Burke AR, Singh RN, Carroll DL, et al. The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials 2012;33:2961-70
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang J, Li X, et al. Selective inhibition of breast cancer stem cells by gold nanorods mediated plasmonic hyperthermia. Biomaterials 2014;35:4667-77
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang H, Wang X, et al. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 2012;33:679-91
   PubMed Web of Science ®Google Scholar
• Ke X-Y, Lin Ng VW, Gao S-J, et al. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials 2014;35:1096-108
   PubMed Web of Science ®Google Scholar
• Qhattal HS, Liu X. Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol Pharm 2011;8:1233-46
   PubMed Web of Science ®Google Scholar
• Song S, Qi H, Xu J, et al. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting. Pharm Res 2014;31:2988-3005
   PubMed Web of Science ®Google Scholar
• Wang D, Huang J, Wang X, et al. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. Biomaterials 2013;34:7662-73
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang J, Kopecek J. Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells. Biomaterials 2012;33:1863-72
   PubMed Web of Science ®Google Scholar
• Morgenroth A, Cartellieri M, Schmitz M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 2007;67:1121-31
   PubMed Web of Science ®Google Scholar
• Wu H, Shi H, Zhang H, et al. Prostate stem cell antigen antibody-conjugated multiwalled carbon nanotubes for targeted ultrasound imaging and drug delivery. Biomaterials 2014;35:5369-80
   PubMed Web of Science ®Google Scholar
• Yang N, Jiang Y, Zhang H, et al. Active targeting docetaxel-PLA nanoparticles eradicate the circulating lung cancer stem like cells and inhibit the liver metastasis. Mol Pharm 2014. [Epub ahead of print]
   Google Scholar
• Andey T, Marepally S, Patel A, et al. Cationic lipid guided short-hairpin RNA interference of annexin A2 attenuates tumor growth and metastasis in a mouse lung cancer stem cell model. J Control Release 2014;184:67-78
   PubMed Web of Science ®Google Scholar
• Taetz S, Bochot A, Surace C, et al. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells. Oligonucleotides 2009;19:103-16
   PubMed Web of Science ®Google Scholar
• Xu Y, Chenna V, Hu C, et al. Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2012;18:1291-302
   PubMed Web of Science ®Google Scholar
• Wang L, Su W, Liu Z, et al. CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials 2012;33:5107-14
   PubMed Web of Science ®Google Scholar
• Jin C, Yang Z, Yang J, et al. Paclitaxel-loaded nanoparticles decorated with anti-CD133 antibody: a targeted therapy for liver cancer stem cells. J Nanopart Res 2013;16:2157
   Google Scholar
• Liu C, Tang DG. MicroRNA regulation of cancer stem cells. Cancer Res 2011;71:5950-4
   PubMed Web of Science ®Google Scholar
• Wang J, Wang C, Meng Q, et al. siRNA targeting Notch-1 decreases glioma stem cell proliferation and tumor growth. Mol Biol Rep 2012;39:2497-503
   PubMed Web of Science ®Google Scholar
• Wu Y, Crawford M, Yu B, et al. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm 2011;8:1381-9
   PubMed Web of Science ®Google Scholar
• Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17:211-15
   PubMed Web of Science ®Google Scholar
• Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009;4:e6816
   PubMed Web of Science ®Google Scholar
• Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008;8:266
   PubMed Web of Science ®Google Scholar
• Li Y, Guessous F, Zhang Y, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 2009;69:7569-76
   PubMed Web of Science ®Google Scholar
• Piao L, Zhang M, Datta J, et al. Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol Ther 2012;20:1261-9
   PubMed Web of Science ®Google Scholar
• Liu CX, Zhao G, Liu J, et al. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J Control Release 2009;140:277-83
   PubMed Web of Science ®Google Scholar
• Pramanik D, Campbell NR, Karikari C, et al. Restitution of Tumor Suppressor MicroRNAs Using a Systemic Nanovector Inhibits Pancreatic Cancer Growth in Mice. Mol Cancer Ther 2011;10:1470-80
   PubMed Web of Science ®Google Scholar
• Yin D, Ogawa S, Kawamata N, et al. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 2013;32:1155-63
   PubMedGoogle Scholar
• Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010;468:824-8
   PubMed Web of Science ®Google Scholar
• Ganesh S, Iyer AK, Morrissey DV, Amiji MM. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 2013;34:3489-502
   PubMed Web of Science ®Google Scholar
• Shen Y, Wang B, Lu Y, et al. A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery. Int J Pharm 2011;414:233-43
   PubMed Web of Science ®Google Scholar
• Park K, Yang JA, Lee MY, et al. Reducible hyaluronic acid-siRNA conjugate for target specific gene silencing. Bioconjug Chem 2013;24:1201-9
   PubMed Web of Science ®Google Scholar
• Dreaden EC, Morton SW, Shopsowitz KE, et al. Bimodal tumor-targeting from microenvironment responsive hyaluronan layer-by-layer (LbL) nanoparticles. ACS Nano 2014;8:8374-82
   PubMed Web of Science ®Google Scholar
• Shigdar S, Qiao L, Zhou S-F, et al. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett 2013;330:84-95
   PubMed Web of Science ®Google Scholar
• Deng ZJ, Morton SW, Ben-Akiva E, et al. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano 2013;7:9571-84
   PubMed Web of Science ®Google Scholar
• Veerabadran NG, Goli PL, Stewart-Clark SS, et al. Nanoencapsulation of stem cells within polyelectrolyte multilayer shells. Macromol Biosci 2007;7:877-82
   PubMed Web of Science ®Google Scholar
• Zhang H, Luo J, Li Y, et al. Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomedicine 2012;8:1116-24
   PubMed Web of Science ®Google Scholar
• Chen W, Shen H, Li X, et al. Synthesis of immunomagnetic nanoparticles and their application in the separation and purification of CD34+ hematopoietic stem cells. Appl Surf Sci 2006;253:1762-9
   Web of Science ®Google Scholar
• Swaminathan SK, Roger E, Toti U, et al. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release 2013;171:280-7
   PubMed Web of Science ®Google Scholar
• Surgery plus chemotherapy (doxorubicin, vincristine and etoposide), mitotane, and tariquidar to treat adrenocortical cancer. 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT00071058?term=NCT00073996&rank=1 [Last accessed 19 August 2014]
   Google Scholar
• Tariquidar and docetaxel to treat patients with lung, ovarian, renal and cervical cancer. 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT00069160?term=NCT00072202&rank=1 [Last accessed 19 August 2014]
   Google Scholar
• Saeki T, Nomizu T, Toi M, et al. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J Clin Oncol 2007;25:411-17
   PubMed Web of Science ®Google Scholar
• Dylla SJ, Beviglia L, Park IK, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008;3:e2428
   PubMed Web of Science ®Google Scholar
• Curiel TJ. Immunotherapy: a useful strategy to help combat multidrug resistance. Drug Resist Updat 2012;15:106-13
   PubMedGoogle Scholar
• Wang CH, Chiou SH, Chou CP, et al. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine 2011;7:69-79
   PubMed Web of Science ®Google Scholar
• Khramtsov AI, Khramtsova GF, Tretiakova M, et al. Wnt/beta-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome. Am J Pathol 2010;176:2911-20
   PubMed Web of Science ®Google Scholar
• Gurney A, Axelrod F, Bond CJ, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci USA 2012;109:11717-22
   PubMed Web of Science ®Google Scholar
• Shih Ie M, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007;67:1879-82
   PubMed Web of Science ®Google Scholar
• Singh BN, Fu J, Srivastava RK, Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One 2011;6:e27306
   PubMed Web of Science ®Google Scholar
• Lin TL, Matsui W. Hedgehog pathway as a drug target: smoothened inhibitors in development. Onco Targets Ther 2012;5:47-58
   PubMed Web of Science ®Google Scholar
• FAK inhibition program: VS-6063 product profile. 2013. Available from: http://www.verastem.com/products/vs-6063.aspx [Last accessed 19 August 2014]
   Google Scholar
• Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010;28:275-80
   PubMed Web of Science ®Google Scholar
• Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009;458:904-8
   PubMed Web of Science ®Google Scholar
• Zhang B, Strauss AC, Chu S, et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010;17:427-42
   PubMed Web of Science ®Google Scholar
• Matsubara S, Ding Q, Miyazaki Y, et al. mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions. Sci Rep 2013;3:3230
   PubMedGoogle Scholar
• Ma S, Lee TK, Zheng BJ, et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27:1749-58
   PubMed Web of Science ®Google Scholar
• Cammareri P, Scopelliti A, Todaro M, et al. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res 2010;70:4655-65
   PubMedGoogle Scholar
• Burkhardt JK, Hofstetter CP, Santillan A, et al. Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench. J Clin Neurosci 2012;19:1568-72
   PubMed Web of Science ®Google Scholar
• Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009;23:43-52
   PubMed Web of Science ®Google Scholar
• Yang ZJ, Wechsler-Reya RJ. Hit ‘Em where they live: targeting the cancer stem cell niche. Cancer Cell 2007;11:3-5
   PubMed Web of Science ®Google Scholar
• Venkatesha VA, Parsels LA, Parsels JD, et al. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia 2012;14:519-25
   PubMed Web of Science ®Google Scholar
• Rao W, Bellotti A, Littrup PJ, et al. Nanoparticle-encapsulated doxorubicin enhances cryoablation of cancer stem-like cells. Technology 2014;2:28-35
   Google Scholar